Showing 5641-5650 of 19383 results for "".
RISK Cohort Study in Crohn's Disease
https://reachmd.com/programs/crohns-colitis-foundation-perspectives/risk-cohort-study-crohns-disease/9924/Lu Ann Cahn talks w/ Dr. Piccoli about the RISK study that enrolled 1,800 patients & collected a variety of info to learn more about the immune systemPancreatic Cancer: Associated Signs, Symptoms, Risk Factors and Treatment Approaches
https://reachmd.com/programs/project-oncology/pancreatic-cancer-associated-signs-symptoms-and-risk-factors-and-treatment-approaches/9552/Though Pancreatic Cancer is the 9th most common cancer, overall, it’s the number 4 cause of cancer deaths.What Lies Beneath the Simple Ankle Sprain
https://reachmd.com/programs/clinicians-roundtable/what-lies-beneath-the-simple-ankle-sprain/3527/Commonly perceived as a minor injury, ankle sprains are dismissed by many athletes, in particular, who are encouraged to shake it off, play through pain, and pursue some simple rehab as their game and practice schedule allows. Yet there is more to simple ankle sprains than we may realize, includingAlbuterol-Budesonide Rescue for Asthma: MANDALA Safety and Use Patterns
https://reachmd.com/programs/Audioabstracts/albuterol-budesonide-rescue-asthma-mandala/54186/A recent analysis from the MANDALA trial explores patterns of use and safety of as-needed albuterol-budesonide rescue therapy in adults with moderate-to-severe asthma receiving maintenance treatment. Tune in to learn how patients used their rescue inhaler in the study and what these findings may meaThe Past, Present, and Future of Metastatic Breast Cancer Care
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/the-past-present-and-future-of-metastatic-breast-cancer-care/39718/Metastatic breast cancer care has evolved dramatically over the past century, driven by advances in our understanding of tumor biology and systemic therapy. From early insights into the role of estrogen to the development of HER2-targeted treatments and precision medicine approaches, these milestoneUpdates in AML Care: Evolving ASH Guidelines for Older Adults
https://reachmd.com/programs/on-the-frontlines-of-amlall/aml-ash-treatment-guidelines-older-adults/54350/Recent updates to the American Society of Hematology (ASH) guidelines are reshaping our treatment approach for older adults with AML. Dr. Shelina Ramnarine sits down with Dr. Mikkael Sekeres to review the newest recommendations on antileukemic therapy, venetoclax-based regimens, and the integrationBiomarker-Guided Treatment in ER+, HER2- Metastatic Breast Cancer
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/biomarker-guided-treatment-er-her2-metastatic-breast-cancer/39723/Biomarker testing has become a cornerstone of personalized care in ER-positive, HER2-negative (ER+, HER2-) metastatic breast cancer, shaping how therapies are selected and sequenced over time. Advances in genomic profiling are improving our understanding of treatment resistance and enabling more preFace Value with Modern Aesthetics: 2025 EYECODE Protocol Update Part 3
https://reachmd.com/series/face-value/face-value-with-modern-aesthetics-2025-eyecode-protocol-update-part-3/54626/In the final episode of this 3-part series, Modern Aesthetics medical editor Dr. Saami Khalifian, board member Dr. Sheila Barbarino, and Dr. John Fezza wrap up their discussion on the 2025 EYECODE Protocol Update. This episode breaks down what injectors should do rather than sending their patient toMASLD and MASH in Focus: Clinical Priorities and Promising Pathways
https://reachmd.com/programs/clinicians-roundtable/masld-mash-clinical-priorities-pathways/39659/From early metabolic risks to advanced liver disease, the progressive burden associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) requires timely, informed care. Hear from Dr. Peter Buch as he shares practical guAdvancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
https://reachmd.com/programs/project-oncology/endometrial-cancer-molecular-target-therapies/39933/Our approach to treating of endometrial cancer is rapidly evolving beyond traditional immunotherapy and towards cellular therapies, bispecifics, and antibody-drug conjugates. Hear from Dr. Casey Cosgrove as he shares expert insights on the latest developments. Dr. Cosgrove is an Assistant Professor